SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on August 7, 2025. The filing serves to report the Company's financial results for the quarter ended June 30, 2025, as detailed in a press release furnished as Exhibit 99.1. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol ATHA.
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text provided.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It solely indicates that results for the quarter ended June 30, 2025, have been issued.
Guidance, Outlook, and Risks
Regulation FD Disclosure: The Company utilizes various channels for material disclosures, including its website, investor relations portal, and social media accounts (X, LinkedIn, Instagram, Facebook). Investors are encouraged to monitor these channels for updates on product candidates and other material matters.
Unusual Items: No unusual items or specific guidance figures are detailed in the text of this 8-K form.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release dated August 7, 2025) for specific Q2 2025 financial figures (revenue, net loss, cash position).
- Verify the Company's cash runway and burn rate, as these are critical for pre-revenue biopharmaceutical firms.
- Check the Company's social media channels and investor relations website for any additional updates on clinical trial progress or product candidate status.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.